长春高新(000661.SZ)：控股子公司两款药品新纳入国家医保目

Core Insights - Changchun High-tech (000661.SZ) announced that its subsidiary, Changchun Jinsai Pharmaceutical Co., Ltd., has two products included in the National Medical Insurance Directory for 2025, namely Jinsai Zeng (long-acting growth hormone injection) and Meishiya (oral suspension of medroxyprogesterone acetate) [1][2] Group 1: Jinsai Zeng - Jinsai Zeng is the world's first long-acting growth hormone approved for market in January 2014, with indications for growth hormone deficiency in children, Turner syndrome, and idiopathic short stature [1] - It is the only long-acting growth hormone product in China with over 150,000 real-world data points validating its long-term efficacy and safety [1] - Ongoing clinical trials include Phase III for adult growth hormone deficiency and Phase II for short stature in children due to being born small for gestational age, indicating potential for broader patient treatment needs [1] Group 2: Meishiya - Meishiya, developed by Bosheng Pharmaceutical Co., Ltd., has been exclusively licensed to Jinsai Pharmaceutical for distribution in mainland China, Hong Kong, Macau, and Singapore since 2024 [2] - Approved indications include treatment for anorexia in patients with acquired immunodeficiency syndrome and significant weight loss due to cachexia in cancer patients [2] - The product utilizes innovative nanotechnology to address clinical issues faced by cachexia patients, providing faster and more effective treatment, and has been recommended in clinical guidelines for cancer-related anorexia-cachexia syndrome [2]